Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

NCT05186506 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT05186506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05186506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer
Lead sponsor
Sichuan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2022
Completion date
December 20, 2028
Enrollment
152 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy, alk fusion protein expression, non-small cell lung cancer